On April 25, 2023, 贝博体育 (1875.HK) and Shanghai Escugen BiotechnologyCo., Ltd. ("Escugen Biotechnology  ") achieved an in-depth strategic collaboration for the development and production of antibody-drug conjugate (贝博体育) from late clinical stage to commercialization.

According to this cooperation agreement, 贝博体育 will provide full support to Escugen Biotechnology in the production of key clinical batches, process characterization and validation (PC/PV), new drug application and commercialization of 贝博体育 projects in China/US/Europe with its extensive experience in the whole value chain of drug development, the commercial advantage of integrating 贝博体育 antibody, drug substance and formulation in one location, and the quality system validated by regulatory units. Both parties have entered into a long-term strategic cooperation and will fully utilize their respective advantages and resources to achieve win-win cooperation in the 贝博体育 field.

Dr. Jun Liu, CEO of 贝博体育, said:
"We are very pleased to enter into a strategic collaboration with Escugen Biotechnology to jointly drive the development and commercialization of 贝博体育 drugs. Escugen Biotechnology is a global Best/First-in-Class company with a pipeline of products that have both druggability and market potential. 贝博体育 has been engaged in 贝博体育 drug development for more than 10 years and has rich experience in 贝博体育 development and production; as one of the few companies that have commercial production lines integrating   antibody intermediate, 贝博体育 DS and 贝博体育 DP, and also one of the leading CDMO service companies in the world that have complete 贝博体育 industry line, it has a capacity of 20,000 liters of antibody, several 500 liters of 贝博体育 drug substance and 50,000 pcs of formulation per batch. With a proven quality system, it may effectively support the development and large-scale commercialization of Escugen Biotechnology's new drugs. With our one-stop service advantage, we look forward to serving more 贝博体育 drug development companies to accelerate drug development and production, and fulfill the unmet clinical needs for the benefit of patients.”

Dr. Qing Zhou, founder and CEO of Escugen Biotechnology, said:
"贝博体育 drugs have become an industry hotspot, and our product pipeline has entered the late clinical stage. In the 贝博体育 field, 贝博体育 is one of the few CDMO companies that can meet the requirement of one-site production from antibody to 贝博体育 drug substance and formulation. In addition, 贝博体育 has a complete 贝博体育 analysis technology platform and can perform independent analysis for key quality attributes. It is believed that this in-depth strategic cooperation will provide production guarantee for Escugen Biotechnology. With the help of strategic CDMO partners, Escugen Biotechnology will continue to focus on innovative new 贝博体育 drug development with unmet clinical needs as the guide. Through integrating antibody and 贝博体育 platform technology innovation, target innovation and clinical development pathway differentiation, Escugen Biotechnology will continue to create innovative 贝博体育 products for the benefit of patients worldwide.